BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou J, Yu X, Hou L, Zhao J, Zhou F, Chu X, Wu Y, Zhou C, Su C. Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer. Lung Cancer 2021;153:143-9. [PMID: 33508527 DOI: 10.1016/j.lungcan.2021.01.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Guo H, Zhang J, Qin C, Yan H, Liu T, Hu H, Tang S, Tang S, Zhou H. Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives. Cells 2022;11:3200. [DOI: 10.3390/cells11203200] [Reference Citation Analysis]
2 Yu W, Yuan X, Ye F, Mao C, Li J, Zhang M, Chen D, Xia S. Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma. Immunotherapy 2022;:0. [PMID: 36169194 DOI: 10.2217/imt-2022-0178] [Reference Citation Analysis]
3 Zhang B, Zeng J, Zhang H, Zhu S, Wang H, He J, Yang L, Zhou N, Zu L, Xu X, Song Z, Xu S. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Front Immunol 2022;13:974581. [DOI: 10.3389/fimmu.2022.974581] [Reference Citation Analysis]
4 Gao G, Ni J, Wang Y, Ren S, Liu Z, Chen G, Gu K, Zang A, Zhao J, Guo R, He J, Lin X, Pan Y, Ma Z, Wang Z, Fan M, Liu Y, Cang S, Yang X, Li W, Wang Q, Zhou C. Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration. Transl Lung Cancer Res 2022;11:964-74. [PMID: 35832447 DOI: 10.21037/tlcr-22-22] [Reference Citation Analysis]
5 Shi AP, Tang XY, Xiong YL, Zheng KF, Liu YJ, Shi XG, Lv Y, Jiang T, Ma N, Zhao JB. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer. Front Immunol 2021;12:785091. [PMID: 35111155 DOI: 10.3389/fimmu.2021.785091] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
6 Ma L, Diao B, Huang Z, Wang B, Yu J, Meng X. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Commun (Lond) 2021. [PMID: 34699691 DOI: 10.1002/cac2.12229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Zhang S, Li S, Cui Y, Cheng Y. [Research Advances on Transformation to Small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2021;24:729-33. [PMID: 34696545 DOI: 10.3779/j.issn.1009-3419.2021.101.28] [Reference Citation Analysis]
8 Yaegashi LB, Baldavira CM, Prieto TG, Machado-Rugolo J, Velosa APP, da Silveira LKR, Assato A, Ab'Saber AM, Falzoni R, Takagaki T, Silva PL, Teodoro WR, Capelozzi VL. In Situ Overexpression of Matricellular Mechanical Proteins Demands Functional Immune Signature and Mitigates Non-Small Cell Lung Cancer Progression. Front Immunol 2021;12:714230. [PMID: 34484217 DOI: 10.3389/fimmu.2021.714230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]